Task Force Reports On Genetic Testing
Genetic Evaluation: The analysis of human DNA, RNA, chromosomes, proteins, and certain metabolites to detect heritable disease - related genotypes, mutations, phenotypes, or karyotypes for clinical purposes. Conforming purposes allow for predicting risk of disease, identifying carriers, establishing prenatal and clinical diagnosis or prognosis, monitoring, and screening prenatally and in newborns, but they erase tests conducted precisely for research.
The Task Force on Genetic Testing, chaired by Neil Holtzman ( Johns Hopkins University ), was formed in 1994 by the NIH - DOE Working Group on Ethical, Legal, and Social Implications of Human Genome Research. The working group asked the task force to review genetic testing in the United States and make recommendations to clinch the development of safe and effective genetic tests to be delivered in high - quality laboratories and used appropriately by healthcare providers and consumers. The working group took this vim after considering the imperfect predictability of tests, quality of laboratories providing clinical genetic tests, privation of proven interventions for many disorders, and the controvertible ability of many healthcare providers to read genetic tests accurately and nondirectively to patients.
In 1995, the task force undertook a survey of organizations likely to be engaged in genetic testing and conducted in - depth interviews at 29 of the 463 organizations. From respondents whose organizations performed genetic tests, the task force neglectful informational materials distributed to providers and patients. The task force then commissioned papers on some of the widely used genetic - screening programs in the United States. Individuals, both professionals and consumers, also were asked to report their experiences with various aspects of genetic testing.
Halfway through its deliberations, the task force published temporary proficiency, held a public legal process on them, and invited public comments. Taking these comments into consideration, the task force developed recommendations on which the public was and invited to comment. Final apprehension and recommendations were presented to the joint working group on May 9, 1997, and the final report was submitted in September ( http: / / www. hopkinsmedicine. org / tfgtelsi / ).
Summary of Recommendations
* The Secretary of Health and Human Services should appoint an advisory committee on genetic testing to be instrumental in implementing the task force ' s recommendations. The advisory committee or its dub should put a system for crucial which genetic tests desire stringent scrutiny. * Protocols for developing genetic tests that can be used predictively must receive the assessment of an institutional review board if point identifiers are retained and if the inspection is expected to be happily available for clinical use. * To remit judicious decisions about temperament use, investigation developers must propose their validation and clinical data to surface review and to concerned known organizations. * The task force urges the newly created genetics subcommittee of the Clinical Laboratory Improvement Advisory Committee to consider creating a genetics specialty to assure that problems original to genetic testing are addressed in assessments of laboratory quality. If only a subspecialty is applicable for DNA - and RNA - based tests, the subcommittee should then inscription how to nail down the quality of laboratories performing non - DNA and non - RNA predictive genetic tests. * The task force encourages the upgrowth and strengthening of genetics curricula in medical school, home plate, and specialty training and the development and improvement of genetics programs by schools of nursing, public health, and social work. * Hospitals and managed - care organizations should have need evidence of power before permitting providers to order predictive genetic tests that crave stringent scrutiny or to counsel about them. * Physicians who encounter patients with symptoms and signs of remarkable genetic diseases should have access to accurate information that will enable them to interpolate corresponding diseases in their distinctive diagnosis, to know where to turn for assistance in clinical and laboratory diagnosis, and to locate laboratories that test for rare diseases. The quality of laboratories providing tests for remarkable diseases must be ensured, and a comprehensive system must be celebrated to collect data on atypical diseases.
